September 2025 in “Journal of the Pakistan Medical Association” Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
May 2025 in “Preprints.org” Unique microRNA patterns can help diagnose and treat severe alopecia areata.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
November 2024 in “Journal of Cutaneous and Aesthetic Surgery” Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.
September 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
November 2023 in “Journal of Investigative Dermatology” The study identified key immune cell differences between mild and severe alopecia areata.
September 2023 in “Dermatology and Therapy” Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
June 2023 in “Skin Research and Technology” High-resolution MRI can distinguish between tertiary androgenetic alopecia and severe alopecia areata by measuring scalp and tissue thickness and hair follicle depth.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
June 2023 in “British Journal of Dermatology” Baricitinib was effective and safe for severe hair loss treatment over 6 months.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
August 2025 in “Journal of the American Academy of Dermatology” Combining PRP with microneedling and minoxidil may help treat severe hair loss.
November 2022 in “Clinical, Cosmetic and Investigational Dermatology” The combined treatment for hair loss is effective, easy to use, and has mild side effects.
56 citations
,
June 2001 in “European journal of cardiovascular prevention & rehabilitation” Early balding linked to higher heart disease risk.
15 citations
,
July 2011 in “Americanae (AECID Library)” Higher zinc intake may reduce hair loss after bariatric surgery.
7 citations
,
January 2022 in “SAGE open medical case reports” Upadacitinib successfully treated a child's severe skin and hair loss issues.
1 citations
,
January 2026 in “Dermatology Reports” Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.
1 citations
,
August 2011 in “DOAJ (DOAJ: Directory of Open Access Journals)” Higher zinc and iron intake leads to less hair loss after bariatric surgery.